BG107370A - Novel interferon for treatment of multiple sclerosis - Google Patents
Novel interferon for treatment of multiple sclerosisInfo
- Publication number
- BG107370A BG107370A BG107370A BG10737002A BG107370A BG 107370 A BG107370 A BG 107370A BG 107370 A BG107370 A BG 107370A BG 10737002 A BG10737002 A BG 10737002A BG 107370 A BG107370 A BG 107370A
- Authority
- BG
- Bulgaria
- Prior art keywords
- multiple sclerosis
- treatment
- beta2
- inf
- interferon
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 2
- 102000014150 Interferons Human genes 0.000 title 1
- 108010050904 Interferons Proteins 0.000 title 1
- 229940079322 interferon Drugs 0.000 title 1
- 229920001184 polypeptide Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21204600P | 2000-06-16 | 2000-06-16 | |
| US09/881,050 US20020025304A1 (en) | 2000-06-16 | 2001-06-15 | Novel interferon for the treatment of multiple sclerosis |
| PCT/US2001/041022 WO2001095929A2 (en) | 2000-06-16 | 2001-06-18 | Interferon for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107370A true BG107370A (en) | 2003-11-28 |
Family
ID=26906704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107370A BG107370A (en) | 2000-06-16 | 2002-12-11 | Novel interferon for treatment of multiple sclerosis |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20020025304A1 (xx) |
| EP (1) | EP1289541A2 (xx) |
| JP (1) | JP2004505021A (xx) |
| KR (1) | KR20030009529A (xx) |
| CN (1) | CN1436086A (xx) |
| AU (1) | AU2001267099A1 (xx) |
| BG (1) | BG107370A (xx) |
| BR (1) | BR0111852A (xx) |
| CA (1) | CA2413077A1 (xx) |
| CZ (1) | CZ20024094A3 (xx) |
| EE (1) | EE200200693A (xx) |
| HU (1) | HUP0300787A2 (xx) |
| IL (1) | IL152996A0 (xx) |
| LT (1) | LT2002123A (xx) |
| MX (1) | MXPA02012308A (xx) |
| NO (1) | NO20025964L (xx) |
| NZ (1) | NZ522849A (xx) |
| PL (1) | PL359562A1 (xx) |
| RU (1) | RU2003100517A (xx) |
| SI (1) | SI21080A (xx) |
| SK (1) | SK17612002A3 (xx) |
| WO (1) | WO2001095929A2 (xx) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1565205A4 (en) * | 2002-11-18 | 2006-07-05 | Maxygen Inc | INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES |
| US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
| EP1712992A1 (en) * | 2005-04-11 | 2006-10-18 | Sony Ericsson Mobile Communications AB | Updating of data instructions |
| US8895700B2 (en) | 2010-02-18 | 2014-11-25 | Janssen Biotech, Inc. | Monkey homolog of human interferon omega |
| CN109071627B (zh) | 2016-02-05 | 2023-04-04 | 奥里尼斯生物科学私人有限公司 | Cd8结合剂 |
| CN110573172A (zh) | 2017-02-06 | 2019-12-13 | 奥里尼斯生物科学有限公司 | 靶向的工程化干扰素及其用途 |
| IL268346B2 (en) | 2017-02-06 | 2024-08-01 | Orionis Biosciences BV | Targeted chimeric proteins and their uses |
| US20240309062A1 (en) * | 2023-03-16 | 2024-09-19 | A-Alpha Bio | Interferon alpha-2 variants |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372206B1 (en) * | 1989-03-02 | 2002-04-16 | University Of Florida | Orally-administered interferon-TAU compositions and methods |
| HUT76099A (en) * | 1994-05-10 | 1997-06-30 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis |
| AU761577C (en) * | 1997-12-08 | 2004-02-05 | Genentech Inc. | Human interferon-epsilon: a type I interferon |
| EP1082132A1 (en) * | 1998-05-29 | 2001-03-14 | Biogen, Inc. | Recombinant human interferon beta-1a (ifn-beta-1a) formulation |
| EP1141296A2 (en) * | 1998-09-18 | 2001-10-10 | ZymoGenetics, Inc. | Interferon-epsilon |
| AU2001255380A1 (en) * | 2000-04-14 | 2001-10-30 | Zymogenetics Inc. | Human interferon, zinf2 |
-
2001
- 2001-06-15 US US09/881,050 patent/US20020025304A1/en not_active Abandoned
- 2001-06-18 HU HU0300787A patent/HUP0300787A2/hu unknown
- 2001-06-18 JP JP2002510107A patent/JP2004505021A/ja active Pending
- 2001-06-18 KR KR1020027017090A patent/KR20030009529A/ko not_active Application Discontinuation
- 2001-06-18 CA CA002413077A patent/CA2413077A1/en not_active Abandoned
- 2001-06-18 SK SK1761-2002A patent/SK17612002A3/sk unknown
- 2001-06-18 SI SI200120032A patent/SI21080A/sl not_active IP Right Cessation
- 2001-06-18 IL IL15299601A patent/IL152996A0/xx unknown
- 2001-06-18 RU RU2003100517/15A patent/RU2003100517A/ru not_active Application Discontinuation
- 2001-06-18 NZ NZ522849A patent/NZ522849A/en unknown
- 2001-06-18 EP EP01944716A patent/EP1289541A2/en not_active Withdrawn
- 2001-06-18 AU AU2001267099A patent/AU2001267099A1/en not_active Abandoned
- 2001-06-18 BR BR0111852-8A patent/BR0111852A/pt not_active Application Discontinuation
- 2001-06-18 MX MXPA02012308A patent/MXPA02012308A/es unknown
- 2001-06-18 CN CN01811184A patent/CN1436086A/zh active Pending
- 2001-06-18 PL PL01359562A patent/PL359562A1/xx not_active Application Discontinuation
- 2001-06-18 EE EEP200200693A patent/EE200200693A/xx unknown
- 2001-06-18 CZ CZ20024094A patent/CZ20024094A3/cs unknown
- 2001-06-18 WO PCT/US2001/041022 patent/WO2001095929A2/en not_active Application Discontinuation
-
2002
- 2002-12-02 LT LT2002123A patent/LT2002123A/xx unknown
- 2002-12-11 BG BG107370A patent/BG107370A/xx unknown
- 2002-12-12 NO NO20025964A patent/NO20025964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004505021A (ja) | 2004-02-19 |
| SI21080A (sl) | 2003-06-30 |
| US20020025304A1 (en) | 2002-02-28 |
| EE200200693A (et) | 2004-06-15 |
| RU2003100517A (ru) | 2004-06-27 |
| NO20025964L (no) | 2003-02-14 |
| BR0111852A (pt) | 2003-05-20 |
| SK17612002A3 (sk) | 2003-08-05 |
| PL359562A1 (en) | 2004-08-23 |
| CZ20024094A3 (cs) | 2003-05-14 |
| WO2001095929A3 (en) | 2002-10-10 |
| AU2001267099A1 (en) | 2001-12-24 |
| LT2002123A (en) | 2003-06-25 |
| CA2413077A1 (en) | 2001-12-20 |
| NO20025964D0 (no) | 2002-12-12 |
| KR20030009529A (ko) | 2003-01-29 |
| IL152996A0 (en) | 2003-06-24 |
| NZ522849A (en) | 2004-05-28 |
| HUP0300787A2 (hu) | 2003-07-28 |
| WO2001095929A2 (en) | 2001-12-20 |
| MXPA02012308A (es) | 2003-04-25 |
| EP1289541A2 (en) | 2003-03-12 |
| CN1436086A (zh) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1033998A4 (en) | METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER | |
| NZ248377A (en) | Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors | |
| DE69914463D1 (en) | Therapeutische chemokine rezeptor antagonisten | |
| ATE406176T1 (de) | Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten | |
| PT735818E (pt) | Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y | |
| EP0457195A3 (en) | Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same | |
| MX9703643A (es) | Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana. | |
| CA2436599A1 (en) | Oral pharmaceutical compositions comprising polyvinylpyrrolidone (pvp) and 5-cnac | |
| HK1030157A1 (en) | Use of consensus interferon and compositions comprising consensus interferon. | |
| AU6020099A (en) | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| BG107370A (en) | Novel interferon for treatment of multiple sclerosis | |
| EP1429800A4 (en) | VACCINE AND METHOD FOR THE TREATMENT OF MOTOR NEURONAL DISEASES | |
| GB0127983D0 (en) | Treatment of micro-organism infection | |
| DE69625682D1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| DE50010519D1 (de) | Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz | |
| KR970701724A (ko) | 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin) | |
| WO2004043373A3 (en) | Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme | |
| IL145722A0 (en) | Pharmaceutical composition comprising growth hormone and interferon | |
| RU2004104335A (ru) | Биологически активные пептиды | |
| WO2004074312A3 (en) | Tryptophyllin peptides and uses thereof | |
| UA66749C2 (en) | Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases | |
| KR950704358A (ko) | 카텝신 l 특이적 저해 폴리펩티드 | |
| AU7435298A (en) | Compositions for enhancing immunosuppressants' pharmaceutical acti vities | |
| NZ336371A (en) | Human gene therapy using DNA/RNA cassette expression systems |